This is a working overview of REV-ERB, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2026-01-14 and is reviewed periodically as new material appears.
Regulatory and sporting contexts treat SR9009 as a prohibited substance in many elite competitions. Its presence on banned lists reflects concerns about performance enhancement and unknown long-term safety. Analytical chemists have developed methods to detect the parent compound and its metabolites in urine and blood. Literature discussions distinguish between in vitro potency, animal pharmacology, and anecdotal human reports. The latter are difficult to verify because products sold online may lack purity or contain different compounds.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms, lipid metabolism, and inflammatory gene expression. In cell and animal experiments, SR9009 alters transcription of clock-controlled genes and metabolic pathways. The compound is not a hormone and does not resemble classical steroid structures. Its activity depends on binding to the ligand-binding domain of REV-ERB, where it can modify corepressor recruitment.
In rodent studies, SR9009 has been reported to increase mitochondrial content in skeletal muscle and improve exercise endurance under some conditions. These findings led to popular descriptions such as an exercise mimetic, although that term oversimplifies the biology. Effects vary by dose, timing, tissue, and model. The compound's influence on circadian pathways means that time of administration can matter in experiments. Whether similar metabolic changes occur in humans remains largely unexplored in controlled published trials.
Pharmacokinetic data for SR9009 are limited in published literature. Some reports indicate low oral bioavailability and rapid clearance in animals, which complicates interpretation of exposure and effect. Researchers often use injected routes in preclinical work to achieve measurable systemic levels. Analytical studies rely on mass spectrometry to detect the parent compound and its metabolites. Questions about tissue distribution, active metabolites, and long-term consequences remain open. Species differences in metabolism can affect observed half-life and target engagement.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic REV-ERB agonist | Binds REV-ERBα and REV-ERBβ in preclinical models |
| Molecular formula | C20H24ClN3O4S | Reported for the parent compound |
| CAS Registry Number | 1379686-30-2 | Common identifier in chemical databases |
| Appearance | Off-white to pale yellow solid | Typical research chemical solid |
| Solubility | Soluble in DMSO and ethanol; low in water | Class: small organic molecule |
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ, also called NR1D1 and NR1D2. These receptors help regulate circadian rhythms and metabolic gene programs. The compound was developed for laboratory research, not as an approved therapeutic. Its identity is distinct from steroid hormones and selective androgen receptor modulators. Scientific interest centers on how REV-ERB activation changes gene expression in cells and animal models.
At the molecular level, SR9009 binds the ligand-binding domain of REV-ERB and strengthens recruitment of corepressor proteins such as NCoR and HDAC3. This increases repression of target genes, including Bmal1 and other clock-controlled and metabolic genes. In rodent studies, such changes have been linked to altered lipid handling, glucose metabolism, and energy expenditure. The precise chain of events between receptor binding and whole-body effects remains an active area of research. Findings in animals do not automatically translate to humans.
SR9009 is a synthetic small molecule studied as a REV-ERB agonist. REV-ERBα and REV-ERBβ are nuclear receptors that help regulate circadian rhythms and metabolic gene expression. The compound was identified in academic screening efforts to find synthetic ligands for these receptors. In cell and animal studies, SR9009 alters transcription of genes involved in lipid and glucose metabolism, and it can shift circadian behavior. It is not an approved therapeutic agent.
Mechanistically, SR9009 binds the ligand-binding domain of REV-ERBα/β and enhances recruitment of corepressor complexes. This represses target genes rather than activating them. Because REV-ERB proteins normally compete with ROR proteins at shared response elements, the net effect depends on tissue and timing. Researchers use SR9009 to probe how nuclear receptor signaling links the clock to metabolism, inflammation, and muscle biology. Findings are largely preclinical, and the precise contribution of each receptor subtype remains under study.
SR9009 is frequently discussed in fitness and research-chemical contexts, yet it has no approved medical indication. Regulatory agencies have not authorized it for human use, and it is not a standard prescription drug. Some sports organizations list it as a prohibited substance because of its potential performance-enhancing properties. Published human data are sparse, so claims about its effects in people often rely on animal models or anecdotal reports. Quality and identity of online materials can vary widely.
SR9009 is a synthetic small molecule developed as a REV-ERB agonist. It binds to REV-ERBα and REV-ERBβ, nuclear receptors that help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, the compound alters lipid and glucose handling and influences skeletal muscle oxidative capacity. Its exact effects in humans remain largely uncharacterized because controlled clinical trials have not been reported. The molecule is frequently described in preclinical literature as a metabolic modulator.
Research interest in SR9009 grew from studies showing improved running endurance in mice after short treatment periods. Those experiments linked the compound to increased mitochondrial content and fatty acid oxidation in muscle, but the findings come from animal models and specific dosing schedules. Independent replication has been limited, and the pathways connecting REV-ERB activation to exercise performance are still being mapped. Whether similar responses occur in humans is an open question.
SR9009 is a synthetic small molecule developed as an agonist of the nuclear receptors REV-ERBα (NR1D1) and REV-ERBβ (NR1D2). These receptors help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, SR9009 alters transcription of genes involved in lipid metabolism, inflammation, and mitochondrial function. It is not an approved medicine, and its pharmacological profile in humans remains largely uncharacterized. The compound is frequently discussed in the context of circadian biology and metabolic research rather than clinical use.
Preclinical reports have linked SR9009 to improved endurance and altered energy expenditure in rodents. Such findings have prompted interest in whether REV-ERB activation can influence skeletal muscle metabolism. However, the reported effects depend on dose, route, and experimental model, and replication across laboratories is limited. Human trials have not established comparable outcomes, so claims about exercise performance remain speculative. The absence of controlled human data is a central limitation in interpreting these observations.
== Metabolism == Metabolic activation is required for PhIP to function as a mutagen. Therefore, the cancer risk posed by PhIP depends on the extent at which PhIP is metabolized. After absorption, PhIP is converted to a genotoxic metabolite in the liver by Phase I enzyme N-oxidation by Cytochrome P-450 1A2 (CYP1A2). PhIP can be further metabolized into a more potent metabolite through O-acetylation by hepatic or colonic N-acetyltransferase 1 (NAT1) and N-acetyltransferase 2 (NAT2), or by sulfotransferases. However, PhIP may also undergo a detoxification pathway through Phase II conjugation reaction via UDP-glucuronosyltransferases (UGTs) to form N-glucuronide conjugates. PhIP's nitrenium ion intermediate is a powerful electrophile that has propensity to form C-8 guanine adducts with the DNA. In addition, some of these metabolic enzymes are inducible and have polymorphic variation. CYP1A2 displays a 40-fold variation in expression among humans and can be induced by smoking, diet, and chronic hepatitis. The expression of UGTs also displays inducibility; however, NATs do not. Individuals can be classified as either rapid or slow N-oxidizers and O-acetylators by assessing CYP1A2 and NAT2 activities. Individuals with the rapid phenotype of either CYP1A2 or NAT2 metabolize PhIP more effectively and are therefore at greater risk of PhIP's carcinogenic metabolite and could be at a higher risk of cancer.
== External links == The menu "science" of the program STRAP provides A comprehensive collection of all flavo-proteins with known 3D-structure. It compares the protein structures to elucidate phylogenetic relationships.
rare-earth element Also called rare-earth metals or used interchangeably with lanthanides. Any of the 17 nearly indistinguishable, silvery-white, soft, heavy metallic elements belonging to a set including the lanthanide series (atomic numbers 57 through 71) as well as scandium and yttrium.
The agency "is also working with its regulatory partners in all 50 state agriculture and health agencies to inform them of the status of the investigative and analytical efforts." The FDA issued an alert to its field personnel that they should block import of wheat gluten from Xuzhou Anying Biologic Technology Development Company Ltd., and subject wheat gluten from China and the Netherlands to increased scrutiny. As a result of the contamination, consumers and pets' rights groups have called for the FDA to take a more active role in ensuring pet food safety. On 2 April 2007, People for the Ethical Treatment of Animals called for the resignation of the FDA's commissioner, Dr. Andrew von Eschenbach. Possibly in response to growing concern about ensuring the safety of the U.S. food supply, on 1 May 2007, Dr. von Eschenbach announced the creation of an Assistant Commissioner for Food Protection to advise on "strategic and substantive food safety and food defense matters." Dr. David Acheson will fill this roll. According to Dr. von Eschenbach, "The protection of America's food supply and therefore the safety of Americans eating food of domestic or international origin is of utmost importance to me as a physician, and to the mission of this agency."
Sources: en.wikipedia.org
== Bibliography == Wagstaff, William Falkland Islands: The Bradt Travel Guide Patrick Watts quoted in Fox, Robert Eyewitness Falklands: A personal account of the Falklands campaign, 1982, p309. The Toponymy of the Falkland Islands as recorded on Maps and in Gazetteers The Permanent Committee on Geographical Names for British Official Use. Southby-Tailyour, Ewen – Falkland Island Shores The European (pub by British Union of Fascists), vol 8, issue 5 (January 1957 p 313-9) PRO HO 45/25740 "Jeffrey Hamm" (British Public Records)
Elizabeth Tracy Mae "Bethe" Wettlaufer (née Parker; born June 10, 1967) is a convicted Canadian serial killer and former registered nurse who confessed to murdering eight senior citizens and attempting to murder six other people in southwestern Ontario between 2007 and 2016. With a total of 14 victims either killed or injured by her actions, she is described as one of the deadliest serial killers in Canadian history.
Aristotle says that the intellect (nous), the ability to think, has no bodily organ (in contrast with other psychological abilities, such as sense-perception and imagination). Aristotle distinguishes between two types of intellect. These are traditionally called the "passive intellect" and the "active (or agent) intellect". He says that the "active (or agent) intellect" is not mixed with the body and suggests that it can exist apart from it. Hence, scholars face the challenge of explaining the relationship between the intellect and the body in Aristotle. According to one interpretation, a person's ability to think (unlike his other psychological abilities) belongs to some incorporeal organ distinct from his body. This would amount to a form of dualism. However, according to some scholars, it would not be a full-fledged Cartesian dualism. This interpretation creates what Robert Pasnau has called the "mind-soul problem" within Aristotelian hylomorphism: if the intellect belongs to an entity distinct from the body, and the soul is the form of the body, then how is the intellect part of the soul? Another interpretation rests on the distinction between the passive intellect and the agent intellect. According to this interpretation, the passive intellect is a property of the body, while the agent intellect is a substance distinct from the body. Some proponents of this interpretation think that each person has his own agent intellect, which presumably separates from the body at death.
Sources: en.wikipedia.org
== Radioactive, primordial, and stable isotopes == Some isotopes/nuclides are radioactive, and are therefore called radioisotopes or radionuclides, whereas others have never been observed to decay radioactively and are called stable isotopes or stable nuclides. For example, 14C is a radioactive form of carbon, while 12C and 13C are stable isotopes. There are about 339 naturally occurring nuclides on Earth, of which 286 are primordial nuclides, meaning that they have existed since the Solar System's formation. Primordial nuclides include 35 nuclides with very long half-lives (over 100 million years) and 251 that are considered "stable nuclides", as they have not been observed to decay. In most cases, if an element has stable isotopes, those isotopes predominate in the elemental abundance found on Earth and in the Solar System. However, in the cases of three elements (tellurium, indium, and rhenium) the most abundant isotope found in nature is actually one (or two) extremely long-lived radioisotope(s) of the element, despite these elements having one or more stable isotopes. Theory predicts that many apparently "stable" nuclides are radioactive, with extremely long half-lives (discounting the possibility of proton decay, which would make all nuclides ultimately unstable). Some stable nuclides are in theory energetically susceptible to other known forms of decay, such as alpha decay or double beta decay, but no decay products have yet been observed, and so these isotopes are said to be "observationally stable".
==== United States ==== 2003: Meloxicam was approved in the US for use in dogs for the management of pain and inflammation associated with osteoarthritis, as an oral (liquid) formulation of meloxicam. 2003 (November): An injectable formulation for use in dogs was approved by the US Food and Drug Administration (FDA). 2004 (October): A formulation for use in cats was approved for use before surgery only. This is an injectable meloxicam, indicated for as a single, one-time dose only, with specific and repeated warnings not to administer a second dose. 2005 (January): The product insert added a warning in bold-face type: "Do not use in cats." 2005: The FDA sent a Notice of Violation to the manufacturer for its promotional materials which included promotion of the drug for off-label use. 2020 (February): A meloxicam injection was approved for use in the United States. Specifically, the FDA granted the approval of Anjeso to Baudax Bio.
== Select publications == Masur, S.K. (1969). "Fine structure of the autotransplanted pituitary of the red eft. Notophthalmus viridescens". Gen. Comp. Endocrin. 12: 12–32. Masur, S.K.; Holtzman, E.; Schwartz, I.L.; Walter, R. (1971). "Correlation between pinocytosis and hydroosmosis induced by neurohypophyseal hormone and mediated by adenosine 3', 5'-cyclic monophosphate". J. Cell Biol. 49: 582–589. Masur, S.K.; Dewal, H.S.; Dinh, T.T.; Erenburg, I.; Petridou, S. (1996). "Myofibroblasts differentiate from fibroblasts plated at low density". Proc. Natl. Acad. Sci. 93: 4219–4223. Maltseva, O; Folger, P; Zekaria, D; Petridou, S; Masur, SK (2001). "Fibroblast growth factor reversal of the corneal myofibroblast phenotype". Invest Ophthalmol Vis Sci. 42: 2490–5. PMID 11581188.. Masur, S.; Kane, C. M. (2001-12-21). "Tapping science's women for the podium". Science. 294 (5551): 2480. doi:10.1126/science.294.5551.2480a. ISSN 0036-8075. PMID 11770518.. Bernstein, AM; Twining, SS; Warejcka, DJ; Tall, E; Masur, SK (2007). "Urokinase receptor cleavage: a crucial step in fibroblast-to-myofibroblast differentiation". Mol Biol Cell. 18: 2716–27. doi:10.1091/mbc.e06-10-0912. PMC 1924808. PMID 17507651.. Masur, Sandra Kazahn (January 2013). "Women in cell biology: a seat at the table and a place at the podium". Molecular Biology of the Cell. 24 (2): 57–60. doi:10.1091/mbc.E12-07-0517. ISSN 1939-4586. PMC 3541963. PMID 23307103.. Masur, Sandra K. (2015-08-01). "Invisible woman?". Trends in Cell Biology. 25 (8): 437–439. doi:10.1016/j.tcb.2015.06.001. ISSN 0962-8924.
Sources: en.wikipedia.org
SR9009 is a synthetic small molecule studied as an agonist of the REV-ERB nuclear receptors. It is not an approved medicine, and its effects in humans are not well characterized.
No. It is a synthetic ligand that binds nuclear receptors, not a steroid or peptide hormone. Its activity depends on receptor binding rather than endocrine secretion.
Clinical evidence is limited. Most published data come from cell and animal experiments. Human safety and efficacy remain uncertain.
It is a synthetic research compound that activates REV-ERB nuclear receptors. It is not an approved drug or dietary supplement. Most information comes from cell and animal studies.